Verde Science Inc (VRCI) 0.0005 $VRCI Verde Science Inc.

New Post Public Reply Private Reply Replies (0) Message Board

Jun 4, 2016 at 12:31 AM

Verde Science Inc (VRCI) 0.0005 $VRCI

Verde Science Inc. Personnel Changes
Marketwired - Fri Nov 27, 10:01PM CST
Verde Science, Inc., (OTCQB:VRCI) announces that Manfred Schauer, Paul Pelosi Jr., Dr. Shantesh Hede, and Manit Patel are no longer with the company. Verde Science will be filling these and other key positions over the next few months.

Verde Science to Sponsor/Present at the Huntington Study Group Annual Conference
GlobeNewswire - Mon Oct 12, 8:15AM CDT
(OTCQB:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabis-based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce it will be sponsoring and presenting at the twenty-third annual Huntington Study Group Conference (http://huntingtonstudygroup.org/) This year's conference, HSG 2015: Building Our Future is being held from October 21-24, 2015 at the Grand Hyatt, Tampa Bay, FL.

Verde Science Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease
GlobeNewswire - Fri Oct 09, 12:15PM CDT
Verde Science, Inc. (OTCQB:VRCI), a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon's Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.

Verde Science Appoints International Banker Manfred A. Schauer
ACCESSWIRE - Mon Jun 01, 7:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 1, 2015 / (PINKSHEETS:VRCI) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
DB: 17.06 (-0.48)

Verde Science Appoints New Chief Financial Officer with Pharmaceutical Sector Experience
ACCESSWIRE - Tue May 12, 5:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).
CRME: 5.11 (+0.04), TLM: 7.99 (unch)

Verde Science Adds John M. E. Percival to the Head of Strategic Development and Member of Board of Directors
ACCESSWIRE - Mon May 04, 5:04AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 4, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand, Ltd where he was responsible for the management of nearly a $500 million in Superannuation and private funds.

Verde Science adds Shantesh Hede, Ph.D As Director of Product Development
ACCESSWIRE - Fri Apr 10, 7:15AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 10, 2015 / (PINKSHEETS:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science's R&D programs on-site with Verde's Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.

News Release Verde Science Pursuing Development of Promising Point-Of-Care Ebola Screening Test
ACCESSWIRE - Mon Nov 10, 8:08AM CST
Image: https://www.baystreet.ca/uploads/verde.jpg

Verde Science Appoints Chief Technology Officer
ACCESSWIRE - Wed Oct 22, 8:03AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png

Verde Science Strengthens Scientific Team
ACCESSWIRE - Thu Oct 02, 8:01AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png

ID Global Corporation Seeks Strategic Partnership with Verde Science, Inc.
PR Newswire - Wed Oct 01, 9:47AM CDT
ID Global Corp. (OTC: IDGC) is pleased to announce that it has signed a binding Memorandum of Understanding (MOU) with Verde Science, Inc. (OTCBB:VRCI), a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems, to begin due-diligence towards a joint venture (Exclusive or non-exclusive) whereby IDGC will provide assistance in raising capital, business advisory services and/or merger discussions.

Verde Science Forms R and D Alliance
ACCESSWIRE - Tue Sep 23, 10:14AM CDT
Richmond, BC / ACCESSWIRE / September 23, 2014 / Verde Science, Inc., (OTCQB: VRCI) a Medical Marijuana Research and Development Company with particular expertise in Aeroponic Growing Systems for the production of pure, efficacious Medical Marajuana, is pleased to announce a Research and Development Alliance with a Mumbai, India based pharmaceutical company that has a record of significant success in the development of novel medical treatment compounds. This new relationship will allow Verde to launch immediately on its THC Pharmaceutical Development Program, and accelerate its R and D operations by about one year. Without this important alliance Verde would have experienced unnecessary delays as it waited for its Research and Development License in Canada. According to Harp Sangha, Verde's Chairman and CEO, "Now we can immediately access the vast treasure of our Indian partner's intellectual capital and tap into a highly educated organization of research scientists in a cost effective manner."

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...